Therapeutic drug monitoring (TDM) for immunosuppressive drugs (ISPs) is a critical component of post-tissue and organ transplantation therapy. This is because ISP drugs have high intra- and inter-subject variability and a narrow therapeutic window. Initially, quantitative analyses of ISPs such as sirolimus, cyclosporine A, tacrolimus, and everolimus used whole blood specimens.
When administering immunosuppressants, clinicians need to individualize a patient’s drug therapy. The goal is to attain an optimal balance between therapeutic efficacy and the probability of adverse effects. Patients present varying pharmacodynamics and pharmacokinetics, so achieving this goal can be challenging.
Patient-centric healthcare has taken center-stage. With the increasing access to information, patients want to play a role in treatment methods and applications. Patient-centric sampling has an important part to play.
Data collected in vivo is mandatory to make informed decisions about drug development and screening. Researchers previously relied on animal models to obtain experimental measurements. The collection of specimens was invasive, labor-intensive, time-consuming, and costly.
At Neoteryx, we work with top scientists and researchers to help facilitate and promote their revolutionary work using Mitra® microsampling devices and Volumetric Absorptive Microsampling (VAMS®) technology.
New work using microsampling in proteomics has transformative implications for science and research, for patient outcomes, and for the way labs do business.
"Having spent years attempting to discover new protein biomarkers, the most interesting and highly motivating thing about our proteomics work is how we might now be able to bring it to the stage where it has impact by improving patient outcomes," says Dr. Stephen Pennington of University College Dublin, whose work in proteomics using Mitra® microsampling devices has indeed begun to garner wider attention.